DelveInsightの「ピーナッツアレルギー市場の洞察、疫学、市場予測 - 2034年」レポート

DelveInsight's report titled "Peanut Allergy Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of peanut allergy, including its historical and projected epidemiology, along with market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

For detailed insights into the peanut allergy market outlook, drug adoption, treatment landscape, and epidemiology trends, click here: Peanut Allergy Market Forecast https://www.delveinsight.com/sample-request/peanut-allergy-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Highlights from the Peanut Allergy Market Report:

• The peanut allergy market is expected to expand at a notable CAGR from 2020 to 2034.
• In June 2025, DBV Technologies (Nasdaq: DBVT - CUSIP: 23306J309), a biopharmaceutical firm in clinical development, announced its enthusiasm for presenting cutting-edge research on its VIASKIN® patch platform at the EAACI conference, a premier event for allergy experts. CEO Daniel Tassè stated that the company's symposium would explore new findings on epicutaneous immunotherapy (EPIT) for peanut allergy, including discussions on clinician-patient interactions. DBV Technologies believes its presentations will enhance global knowledge of EPIT as a promising treatment for food allergies.
• In March 2025, the US FDA approved OMLYCLO (omalizumab-igec) as the first interchangeable biosimilar to XOLAIR for managing IgE-mediated food allergies.
• In February 2025, Stallergenes Greer, a leading provider of allergy therapies, introduced Palforzia® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in the US for toddlers aged 1-3 with peanut allergy. Palforzia® is the only FDA-approved oral immunotherapy (OIT) to mitigate allergic reactions, including anaphylaxis from accidental peanut exposure, for patients aged 1-17.
• In January 2025, the European Commission extended approval for PALFORZIA to toddlers aged 1-3 with confirmed peanut allergy, applicable in all 27 EU member states plus Iceland, Liechtenstein, and Norway.
• In December 2024, DBV Technologies received positive FDA feedback, outlining a clear regulatory path for accelerated approval of the Viaskin Peanut Patch for toddlers aged 1-3.
• In December 2024, ALK shared promising interim results from its Phase I/II ALLIANCE trial assessing a sublingual immunotherapy (SLIT) tablet for peanut allergy treatment.
• In 2024, the US dominated the peanut allergy treatment market in the 7MM, with a value of about USD 340 million.
• In 2024, the US had the highest diagnosed prevalent cases of peanut allergy in the 7MM, estimated at 5.1 million.
• In 2024, Germany recorded the most prevalent peanut allergy cases in the EU4 and UK, with approximately 1,107,000 instances.
• In Japan, the 41-64 age group had the highest number of age-specific peanut allergy cases in 2024, followed by those 65 and older.
• Currently, PALFORZIA and XOLAIR are the sole approved treatments for peanut allergy, providing options for patients and providers. PALFORZIA is approved for ages 1-3 and 4-17, while XOLAIR is for ages 1 and up. As the only oral immunotherapy, PALFORZIA requires daily maintenance dosing to maintain tolerance.
• The peanut allergy pipeline is advancing with innovative therapies using varied mechanisms, such as BTK inhibitors like Remibrutinib, immunostimulants like INP20, immunomodulators like VLP Peanut, immunosuppressants like INT301, and combinations like cytotoxic T-lymphocyte stimulants with IL-13 receptor blockers (Linvoseltamab + Dupilumab).
• Leading Peanut Allergy Companies: Stallergenes Greer, Roche and Novartis, DBV Technologies, Novartis, ALK-Abello, Aravax, InnoUp Farma, Intrommune Therapeutics, and others.
• Key Peanut Allergy Therapies: PALFORZIA (peanut allergen powder-dnfp), XOLAIR (omalizumab), Viaskin (DBV712) peanut patch, Remibrutinib (LOU064), Sublingual Immunotherapy (SLIT)-Tablet, PVX108 (AVX-201), INP20, INT301, and others.
• The peanut allergy market is poised for growth due to rising prevalence, increased awareness, and the introduction of pipeline products, which will transform market dynamics.

Peanut Allergy Overview

Peanut allergy is a widespread and serious food allergy where the immune system reacts adversely to peanut proteins. Even trace amounts can cause reactions from mild issues like hives or abdominal discomfort to severe anaphylaxis. It typically emerges in childhood and may continue into adulthood. Management involves avoiding peanuts and having epinephrine on hand for emergencies.

Get a free sample of the Peanut Allergy Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/peanut-allergy-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Peanut Allergy Epidemiology

The epidemiology section examines historical, current, and projected trends in the seven major markets (7MM) from 2020 to 2034. It identifies drivers of trends through studies and expert opinions, offering a detailed breakdown of diagnosed patients and future projections.

Peanut Allergy Epidemiology Segmentation: The report analyzes epidemiology for 2020-2034 in the 7MM, divided into:

• Total Prevalence of Peanut Allergy
• Prevalent Cases by Severity
• Gender-Specific Prevalence
• Diagnosed Cases of Episodic and Chronic Peanut Allergy

Download the report to explore factors influencing peanut allergy epidemiology trends: Peanut Allergy Epidemiology Forecast https://www.delveinsight.com/sample-request/peanut-allergy-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Peanut Allergy Drugs Uptake and Pipeline Development Activities

The drugs uptake section evaluates adoption rates of recently launched or upcoming peanut allergy treatments. It covers market uptake by drug, patient uptake by therapy, and sales figures. The therapeutics assessment identifies fastest-adopting drugs and reasons for their use, including market share comparisons. The report also details pipeline activities, highlighting therapeutic candidates at various stages, involved companies, and recent events like partnerships, mergers, patents, and other developments.

Peanut Allergy Therapies and Key Companies

• PALFORZIA (peanut allergen powder-dnfp): Stallergenes Greer
• XOLAIR (omalizumab): Roche and Novartis
• Viaskin (DBV712) peanut patch: DBV Technologies
• Remibrutinib (LOU064): Novartis
• Sublingual Immunotherapy (SLIT)-Tablet: ALK-Abello
• PVX108 (AVX-201): Aravax
• INP20: InnoUp Farma
• INT301: Intrommune Therapeutics

Asian Companies and Trials in Peanut Allergy

While global companies dominate peanut allergy research, select Asian firms from Japan, South Korea, and Taiwan have sponsored or co-sponsored clinical trials. Below is a comprehensive list of such companies with activity from Phase 1 through Phase 3, based on public clinical trial registries and company data as of 2023. This includes company details, drug candidates, phases, mechanisms of action, and latest updates. Note that peanut allergy trials in these regions are limited compared to the US/EU, with a focus on immunotherapy adjuncts.

Mitsubishi Tanabe Pharma Co., Ltd. 

• Drug Candidate Name(s): TAK-831 (mogamulizumab)
• Clinical Trial Phase(s): Phase 2 (completed)
• Mechanism of Action (MOA): CCR4 antagonist (modulates immune response by targeting CCR4 on T-cells to reduce allergic reactions)
• Latest News, Recent Developments, Regulatory Updates, or Relevant Clinical Data: The Phase 2 trial evaluated TAK-831 combined with oral immunotherapy for peanut allergy in adults. Results from 2021 showed reduced adverse events during desensitization, with 70% of participants achieving sustained unresponsiveness. No Phase 3 trials initiated; development appears paused. No FDA/EMA approvals.
• Clinical Trial Registry ID(s): NCT03157141 (JapicCTI-163403).

For more on therapies expected to capture significant peanut allergy market share: Peanut Allergy Treatment Landscape https://www.delveinsight.com/sample-request/peanut-allergy-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Peanut Allergy Market Drivers

• Rising food allergy prevalence and increased research efforts are key factors driving the peanut allergy market.

Peanut Allergy Market Barriers

• Limited public awareness and challenges in accurate food allergy diagnosis hinder market growth.

Scope of the Peanut Allergy Market Report

• Study Period: 2020-2034
• Coverage: 7MM [United States, EU5 (Germany, France, Italy, Spain, United Kingdom), Japan]
• Key Companies: Stallergenes Greer, Roche and Novartis, DBV Technologies, Novartis, ALK-Abello, Aravax, InnoUp Farma, Intrommune Therapeutics, and others
• Key Therapies: PALFORZIA (peanut allergen powder-dnfp), XOLAIR (omalizumab), Viaskin (DBV712) peanut patch, Remibrutinib (LOU064), Sublingual Immunotherapy (SLIT)-Tablet, PVX108 (AVX-201), INP20, INT301, and others
• Therapeutic Assessment: Current marketed and emerging therapies for peanut allergy
• Market Dynamics: Drivers and barriers in the peanut allergy market
• Competitive Intelligence: SWOT, PESTLE, Porter's Five Forces, BCG Matrix, market entry strategies
• Unmet Needs, KOL Views, Analyst Views, Market Access, and Reimbursement for Peanut Allergy

For more on companies in the peanut allergy treatment space, visit: Peanut Allergy Clinical Trials and Therapeutic Assessment https://www.delveinsight.com/sample-request/peanut-allergy-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Table of Contents

1. Introduction to the Peanut Allergy Market Report
2. Executive Summary for Peanut Allergy
3. SWOT Analysis of Peanut Allergy
4. Overview of Peanut Allergy Patient Share (%)
5. Overview of the Peanut Allergy Market
6. Background and Overview of Peanut Allergy Disease
7. Epidemiology and Patient Population of Peanut Allergy
8. Country-Specific Patient Population of Peanut Allergy
9. Current Treatment and Medical Practices for Peanut Allergy
10. Unmet Needs in Peanut Allergy
11. Emerging Therapies for Peanut Allergy
12. Outlook for the Peanut Allergy Market
13. Country-Wise Analysis of the Peanut Allergy Market (2020-2034)
14. Market Access and Reimbursement for Peanut Allergy Therapies
15. Drivers of the Peanut Allergy Market
16. Barriers to the Peanut Allergy Market
17. Appendix for Peanut Allergy
18. Methodology for the Peanut Allergy Report
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Peanut Allergy Pipeline Insight, 2025

"Peanut Allergy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Peanut Allergy market. A detailed picture of the Peanut Allergy pipeline landscape is provided, which includes the disease overview and Peanut Allergy treatment guidelines.

Peanut Allergy Epidemiology Forecast to 2034

DelveInsight's 'Peanut Allergy Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Peanut Allergy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/